Tablets

"Tablets" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)

Descriptor ID	D013607
MeSH Number(s)	D26.255.830
Concept/Terms	Tablets Tablets

Below are MeSH descriptors whose meaning is more general than "Tablets".

Chemicals and Drugs [D]
Pharmaceutical Preparations [D26]
Dosage Forms [D26.255]
Tablets [D26.255.830]

Below are MeSH descriptors whose meaning is related to "Tablets".

Below are MeSH descriptors whose meaning is more specific than "Tablets".

Tablets
Tablets, Enteric-Coated

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tablets" by people in this website by year, and whether "Tablets" was a major or minor topic of these publications.

Bar chart showing 28 publications over 13 distinct years, with a maximum of 4 publications in 2001 and 2013 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	4	4
2003	0	1	1
2004	0	2	2
2007	0	1	1
2011	0	1	1
2013	0	4	4
2017	0	1	1
2018	2	2	4
2020	1	1	2
2021	0	2	2
2022	0	2	2
2023	0	3	3
2024	0	1	1

Below are the most recent publications written about "Tablets" by people in Profiles.

Tassorelli C, Onishchenko K, Halker Singh RB, Duan M, Dupont-Benjamin L, Hemstock M, Voller C, McAllister P, Nahas SJ, Gandhi P, Ailani J. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia. 2024 02; 44(2):3331024241235156.

View in: PubMed
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 10; 13(5):261-268.

View in: PubMed
Kalatskaya I, Giovannoni G, Leist T, Cerra J, Boschert U, Rolfe PA. Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Sci Rep. 2023 05 18; 13(1):8067.

View in: PubMed
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.

View in: PubMed
Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5?years: a plain language summary. Neurodegener Dis Manag. 2022 12; 12(6):303-310.

View in: PubMed
Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA, Leist TP. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. Neurodegener Dis Manag. 2022 02 01; 12(1):1-7.

View in: PubMed
Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C, Leist TP. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Front Immunol. 2021; 12:763433.

View in: PubMed
De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Mult Scler. 2022 01; 28(1):111-120.

View in: PubMed
Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs. 2020 Dec; 80(18):1901-1928.

View in: PubMed
Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S, Galazka A. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102572.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement